First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it. The symptoms ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Post hoc data from TAILORx show that adding an anthracycline to taxane-based chemotherapy benefits patients with HR-positive ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the ...

New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...

These surgeries significantly reduced risk of death or cancer recurrence. Women with BRCA1 mutations benefitted most FRIDAY .

Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...

The beloved teacher of 20 years and mother of two is known for her warmth and dedication. She was diagnosed with ovarian cancer for a second time this summer.

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...